

Arum Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5372829/publications.pdf>

Version: 2024-02-01

20
papers

344
citations

933447

10
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

694
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC expression correlates with PD-L1 expression in non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 110, 63-67.	2.0	86
2	Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer. <i>BMC Cancer</i> , 2017, 17, 467.	2.6	32
3	Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 27.	2.6	30
4	ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. <i>Neoplasia</i> , 2017, 19, 354-363.	5.3	27
5	Keratinization of Lung Squamous Cell Carcinoma Is Associated with Poor Clinical Outcome. <i>Tuberculosis and Respiratory Diseases</i> , 2017, 80, 179.	1.8	25
6	Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. <i>Oncology Reports</i> , 2013, 30, 1423-1429.	2.6	17
7	Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer. <i>Journal of Cancer</i> , 2017, 8, 1347-1354.	2.5	17
8	AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. <i>Cancer Letters</i> , 2015, 358, 85-91.	7.2	16
9	Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984679.	3.2	16
10	KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression. <i>Lung Cancer</i> , 2014, 85, 299-305.	2.0	12
11	BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis. <i>Lung Cancer</i> , 2015, 90, 106-110.	2.0	10
12	Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. <i>BMC Cancer</i> , 2018, 18, 1221.	2.6	10
13	Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2019, 60, 1005.	2.2	10
14	Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2267-2273.	1.9	9
15	ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model. <i>Yonsei Medical Journal</i> , 2022, 63, 16.	2.2	9
16	Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. <i>Cancer Biology and Therapy</i> , 2020, 21, 741-748.	3.4	6
17	Medical marijuana utilization in gynecologic cancer patients. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100820.	0.6	6
18	Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation. <i>Journal of Cancer</i> , 2019, 10, 5549-5556.	2.5	4

#	ARTICLE	IF	CITATIONS
19	An Isoform of the Oncogenic Splice Variant AIMP2-DX2 Detected by a Novel Monoclonal Antibody. <i>Biomolecules</i> , 2020, 10, 820.	4.0	1
20	Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0239670.	2.5	1